PT 141 for erectile dysfunction: how the bremelanotide injection works, what studies show in men, typical doses, side effects, and prescription rules.
PT 141 (bremelanotide) is an injectable prescription drug approved in the United States as Vyleesi for low sexual desire in premenopausal women. It is not FDA-approved for erectile dysfunction, and the manufacturer never pursued approval for male ED. Small early studies did report firmer erections in some men, so interest in pt-141 for erectile dysfunction persists — but the evidence in men remains mixed and the drug is only legally available by prescription.
What Is PT-141 (Bremelanotide)?
Bremelanotide is a synthetic peptide that mimics alpha-melanocyte-stimulating hormone and binds melanocortin receptors. It was originally studied as a tanning agent before researchers noticed unexpected effects on sexual arousal.
- Drug class: melanocortin receptor agonist (MC3R and MC4R), not a PDE5 inhibitor.
- Brand name: Vyleesi, approved by the FDA in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Route: subcutaneous injection into the abdomen or thigh.
- Status for men: not approved, not indicated, and sold only as an off-label or gray-market product.
How PT-141 Differs From Viagra and Cialis
PT-141 acts on the brain, targeting receptors in the hypothalamus that sit downstream of dopamine signaling. It aims at desire and central arousal rather than penile blood flow alone.
Sildenafil and tadalafil relax vascular smooth muscle in the penis by blocking the PDE5 enzyme. That difference is exactly why researchers once hoped PT-141 could help men who did not respond to standard ED pills.
| Feature | PT-141 (bremelanotide) | Sildenafil (Viagra) | Tadalafil (Cialis) |
|---|---|---|---|
| FDA-approved use | HSDD in premenopausal women | Erectile dysfunction | ED and benign prostatic hyperplasia |
| How it is taken | Subcutaneous injection | Oral tablet | Oral tablet |
| Primary target | Melanocortin receptors in the brain | PDE5 enzyme and penile blood flow | PDE5 enzyme |
| Studied or labeled dose | 1.75 mg (women); 1.25–10 mg in male research | 50 mg as needed | 10 mg as needed |
| Common side effects | Nausea, flushing, headache, injection site reactions | Headache, flushing, nasal congestion | Headache, back pain, flushing |
What the Research Shows in Men
Most published pt-141 for erectile dysfunction research involves small, short-term trials from the early 2000s using intranasal and injected doses. Some participants reported firmer erections and better intercourse satisfaction roughly 30 to 60 minutes after dosing.
Results were inconsistent. Men with nerve damage from prostate surgery or long-standing diabetes often saw little benefit, and the FDA-approved label does not include men at all. That gap between hopeful forum reports and modest trial data is important to keep in mind.
Interest in pt-141 peptide for men has grown mostly through telehealth marketing and online communities, which frequently outpaces what the peer-reviewed literature actually supports.
Dosing studied in male trials
The pt-141 10mg dosage for men shows up in several early studies and is the figure most often repeated online. Higher doses tended to produce more nausea without clearly better results. Common regimens studied in men have included:
- 1.25 mg and 1.75 mg subcutaneous injections
- 2.5 mg and 5 mg subcutaneous injections
- 7.5 mg and 10 mg subcutaneous injections
- Intranasal doses of 10 mg and 20 mg in older trials
None of these male regimens is FDA-approved, and there is no standard, validated male dose. Dosing for women is a separate matter.
The Approved Use: PT-141 in Women
Vyleesi is labeled for premenopausal women with acquired, generalized HSDD. The pt-141 dosage for women is a single 1.75 mg injection at least 45 minutes before anticipated sexual activity, limited to one dose in 24 hours and no more than eight doses per month.
Whether PT-141 reliably helps women is supported by two phase 3 trials in that specific population. The same confidence does not extend to men, to postmenopausal women, or to people using it purely for performance enhancement.
Do You Need a Prescription for PT-141?
A common question is do you need a prescription for pt-141, and in the United States the answer is yes. Bremelanotide is a prescription-only medicine, and obtaining it without a valid prescription is illegal.
Listings that advertise pt-141 for sale as a "research chemical" are not FDA-approved products. They may be underdosed, mislabeled, or contaminated, and no regulator verifies their sterility or potency. Buying from those sources also means no medical screening for the conditions that make the drug risky.
PT-141 is a prescription drug in the US, and unregulated research-chemical vials are not a legal or safe substitute.
Side Effects and Safety Considerations
Nausea is the most frequently reported side effect, affecting a large share of trial participants, followed by flushing and headache. Other concerns include:
- Injection site reactions such as pain, bruising, or swelling
- Transient increases in blood pressure and small changes in heart rate
- Vomiting, which is more likely at higher doses
- Focal hyperpigmentation — darkening of the gums, skin, or breasts — with repeated use
Bremelanotide is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease. It is not recommended during pregnancy, and it should not be combined casually with other vasoactive drugs.
PT-141 is not a cure for erectile dysfunction and does not treat the underlying vascular, hormonal, neurologic, or psychological causes. Anyone considering it should speak with a healthcare professional about proven options first.
Bottom Line
PT-141 is not FDA-approved for erectile dysfunction in men. Bremelanotide is approved only for hypoactive sexual desire disorder in premenopausal women, at a fixed 1.75 mg injected dose. In men, study results have been inconsistent and no standard dose exists. PT-141 requires a prescription in the United States, and products sold online as research chemicals are unregulated and potentially unsafe.
Frequently Asked Questions
Does PT-141 work for erectile dysfunction?
PT-141 is not FDA-approved for erectile dysfunction, and the manufacturer never sought approval for that use. Some early trials in men reported firmer erections and improved satisfaction, but results were inconsistent, especially in men with nerve damage or long-standing diabetes. It is not considered a reliable replacement for PDE5 inhibitors like sildenafil or tadalafil.
What dose of PT-141 do men use?
There is no approved male dose. Research studies tested single subcutaneous injections ranging from 1.25 mg to 10 mg, and 10 mg is the figure most often discussed online. Higher doses were linked to more nausea and vomiting without clearly better results, so any use in men is off-label and unverified.
Can you buy PT-141 without a prescription?
No. Bremelanotide is a prescription-only medication in the United States, and importing or buying it without a prescription is illegal. Products marketed as research chemicals are not FDA-approved, are not tested for sterility or potency, and may contain incorrect doses or unknown impurities.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.